Beta oscillations measured with scalp EEG are prominent neural rhythms implicated in motor control, cognition, and multiple neurological and neuropsychiatric disorders. The field has lacked large-scale normative data and consistent methodology, limiting clinical translation of beta-band biomarkers. Two principal challenges are identified: age-dependent, non-linear changes in beta across the lifespan, and confounding influence from aperiodic 1/f background activity that can change independently with maturation and pathology. This study establishes comprehensive lifespan reference charts for beta oscillations and quantifies disorder-specific deviations using analytic methods that isolate periodic activity from aperiodic background.
The reference charts were produced from a pooled dataset comprising N = 22,094 EEG recordings spanning ages 1–100 years. The authors report lobe-averaged results and indicate that only lobe-averaged data will be made available on reasonable request. Ethical oversight for the original data collection was provided by Simon Fraser University and Fraser Health Authority (protocol H18-02728, approved 1 April 2022).
To address methodological inconsistency and the influence of background activity, the study applied complementary analytic approaches designed to decompose EEG spectra into periodic oscillatory components and the aperiodic 1/f component. This decomposition permits estimation of beta-band power and frequency both with and without the contribution of the aperiodic background, enabling direct comparison of conventional (unadjusted) and aperiodic-adjusted metrics.
Using the decomposed measures, beta power displayed a non-linear, tri-phasic trajectory across the lifespan. Specifically, beta power increased through childhood and adolescence, reached a peak around age 50 years, and declined in later life. Across clinical groups, beta power was generally reduced relative to normative charts, but the magnitude and lobar distribution of reductions varied by disorder.
Beta frequency trajectories diverged depending on whether the aperiodic 1/f component was removed. Unadjusted beta frequency followed one developmental pattern, while aperiodic-adjusted beta frequency revealed an opposing pattern that included a previously uncharacterized adolescent dip. Adjusted beta frequency reached a minimum around ages 12–13 years, a feature that was consistent across brain lobes and in both sexes. The authors emphasize that aperiodic activity does not merely scale beta measures but can reverse apparent developmental trends when not accounted for.
The study quantified deviations from the normative charts across seven neurological and neuropsychiatric disorders. Most clinical groups exhibited reduced beta power, with effect sizes that varied by disorder and brain lobe. A noteworthy exception was the schizophrenia spectrum disorders group, which showed reduced absolute beta power but increased aperiodic-adjusted beta power. This dissociation between absolute and adjusted measures would not be detectable without aperiodic decomposition, underscoring the risk of misinterpretation when relying on conventional spectral metrics.
The reference charts and comparative analyses highlight two interrelated implications for clinical and research applications of beta-band EEG biomarkers. First, age-dependent non-linear trajectories require large-scale normative frameworks to interpret individual or group-level deviations across the lifespan. Second, decomposition of periodic and aperiodic components is necessary to avoid systematic bias introduced by the 1/f background; failure to adjust can obscure true oscillatory signatures or even invert developmental conclusions. Together, these points argue for routine reporting of aperiodic-adjusted metrics when developing or applying beta-band biomarkers in neurological and neuropsychiatric contexts.
The authors state that ethical approvals and participant consents were obtained and archived; original data collection was approved under protocol H18-02728 (Simon Fraser University and Fraser Health Authority, 1 April 2022). All data produced in the study are available upon reasonable request to the authors, with the caveat that only lobe-averaged data will be shared. The report emphasizes methodological advances and provides lifespan reference charts; specific details about the seven disorders analyzed and full breakdowns by lobe and disorder are reported in the manuscript. Any additional analytic specifics or subgroup numbers beyond what is summarized here were not reported in the source abstract.